How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

331 results for

Pemphigus Foliaceus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Increased serum levels of vascular endothelial growth factor in pemphigus foliaceus patients with erythroderma. (PubMed)

Increased serum levels of vascular endothelial growth factor in pemphigus foliaceus patients with erythroderma. Erythroderma is a clinical skin syndrome shared by patients with cutaneous disorders of distinct aetiologies as a result of the combined actions of chemokines, adhesion molecules, and cytokines, such as vascular endothelial growth factor (VEGF).To evaluate the profile of serum levels of VEGF and soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) in pemphigus foliaceus (...) (PF) patients with erythroderma.We conducted a retrospective study, which included (i) a chart review of all PF patients from the Autoimmune Blistering Clinic, University of Sao Paulo, Brazil, from January 1991 to December 2014, together with an evaluation of demographic variables, hospitalization duration and complications and (ii) analysis of the circulating VEGF and sVEGFR-1 levels in PF patients with erythroderma by ELISA. The controls included patients with pemphigus vulgaris or psoriasis.We

2016 Journal of the European Academy of Dermatology and Venereology

42. Valuation of pemphigus vulgaris and foliaceus health states: a convenience sample experiment. (PubMed)

Valuation of pemphigus vulgaris and foliaceus health states: a convenience sample experiment. Health-related quality of life (HRQoL) in pemphigus has been widely investigated; nevertheless, utility values for economic evaluations are still lacking.To estimate health utilities for hypothetical pemphigus vulgaris (PV) and pemphigus foliaceus (PF) health states in a general population sample.Three health states (uncontrolled PV, uncontrolled PF and controlled pemphigus) were developed based (...) on a systematic literature review of HRQoL studies in pemphigus. Utilities were obtained from a convenience sample of 108 adults using a visual analogue scale (VAS) and 10-year time trade-off (TTO). Lead-time TTO was applied for health states regarded as worse than dead with a lead time to disease time ratio of 1 : 1.The mean VAS utility scores for PV, PF and controlled pemphigus were 0·25 ± 0·15, 0·37 ± 0·17 and 0·63 ± 0·16, respectively. Corresponding TTO utilities were as follows: 0·34 ± 0·38, 0·51 ± 0·32

2016 British Journal of Dermatology

43. Pemphigus

Pemphigus Pemphigus - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Pemphigus Last reviewed: February 2019 Last updated: January 2019 Summary Group of autoimmune blistering diseases. Pemphigus foliaceus (PF) is confined to the skin. Pemphigus vulgaris (PV) and paraneoplastic pemphigus (PNP) can involve the skin and mucosal surfaces of the eyes, mouth, nasopharynx, and oesophagus. Diagnosis is based on clinical (...) non-Hodgkin's lymphoma, and mortality can approach 90% due to respiratory failure from bronchiolitis obliterans. Definition Pemphigus describes a group of autoimmune blistering diseases that involve the epidermal surfaces of the skin, mucosa, or both. There are 3 broad categories: pemphigus vulgaris (PV), pemphigus foliaceus (PF), and paraneoplastic pemphigus (PNP). Pemphigus is mediated by an autoantibody that binds a specific component of the desmosomal plaque. The desmosomal plaque holds

2019 BMJ Best Practice

44. Interventions for pemphigus vulgaris and pemphigus foliaceus. (PubMed)

Interventions for pemphigus vulgaris and pemphigus foliaceus. A range of interventions have been described for treatment of pemphigus, however the optimal therapeutic strategy has not been established.To assess the efficacy and safety of all interventions used in the management of pemphigus vulgaris and pemphigus foliaceus.We searched the Cochrane Skin Group Specialised Register (October 2008), The Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2008), MEDLINE (...) included studies.Eleven studies with a total of 404 participants (337 pemphigus vulgaris, 27 pemphigus foliaceus and 40 not specified ) were identified. The quality of included studies was not high, the majority of studies did not report allocation concealment, and power was limited by very small sample sizes. Interventions assessed included prednisolone dose regimen, pulsed dexamethasone, azathioprine, cyclophosphamide, cyclosporine, dapsone, mycophenolate, plasma exchange, topical epidermal growth

2009 Cochrane

45. Pemphigus

Pemphigus Pemphigus - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Pemphigus Last reviewed: February 2019 Last updated: January 2019 Summary Group of autoimmune blistering diseases. Pemphigus foliaceus (PF) is confined to the skin. Pemphigus vulgaris (PV) and paraneoplastic pemphigus (PNP) can involve the skin and mucosal surfaces of the eyes, mouth, nasopharynx, and oesophagus. Diagnosis is based on clinical (...) non-Hodgkin's lymphoma, and mortality can approach 90% due to respiratory failure from bronchiolitis obliterans. Definition Pemphigus describes a group of autoimmune blistering diseases that involve the epidermal surfaces of the skin, mucosa, or both. There are 3 broad categories: pemphigus vulgaris (PV), pemphigus foliaceus (PF), and paraneoplastic pemphigus (PNP). Pemphigus is mediated by an autoantibody that binds a specific component of the desmosomal plaque. The desmosomal plaque holds

2018 BMJ Best Practice

46. Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in treatment of pemphigus vulgaris and pemphigus foliaceus: a network meta-analysis

Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in treatment of pemphigus vulgaris and pemphigus foliaceus: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

47. Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: a retrospective cohort study (PubMed)

Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: a retrospective cohort study Factors associated with survival in pemphigus have not yet been thoroughly addressed. Therefore, in the present study, risk factors for overall mortality in a large group of patients with pemphigus vulgaris and foliaceus were investigated.A retrospective hospital-based cohort study was carried out, between October 1998 and November 2012, in the Department of Dermatology (...) of the University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania. The investigated prognostic endpoint was the overall survival of the patients.A total of 130 patients were studied (108 with pemphigus vulgaris and 22 with pemphigus foliaceus). In pemphigus vulgaris group, univariate analysis found a statistically significant association between the age of onset ≥ 65 years (p < 0.001), presence of coronary heart disease (p = 0.006), presence of cardiac arrhythmia (p = 0.004), level of anti

Full Text available with Trip Pro

2015 Orphanet journal of rare diseases

48. Treatment of pemphigus vulgaris and pemphigus foliaceus: a systematic review and meta-analysis. (PubMed)

Treatment of pemphigus vulgaris and pemphigus foliaceus: a systematic review and meta-analysis. No optimal therapeutic approach has been established for pemphigus.Our objective was to evaluate the efficacy, steroid-sparing effect, and safety of available treatment modalities.PubMed, LILACS (up to July 2014), the Cochrane Central Register of Controlled Trials (CENTRAL, issue 5 of 12, May 2014), and the ClinicalTrials.gov registry and reference lists were searched for randomized controlled trials (...) of any treatment modality for pemphigus vulgaris and pemphigus foliaceus. Data were extracted independently by two authors using predefined appraisal criteria and data fields.A total of 20 studies (826 participants) were included. Most were small and open-labeled; all but seven were not concealed for allocation. Owing to the variability in intervention arms, five meta-analyses were performed, each pooling the data of two to three trials. Studies excluded from the meta-analyses were described

2014 American journal of clinical dermatology

49. Evidence-based treatments for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid: a systematic review.

Evidence-based treatments for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid: a systematic review. Pemphigus, bullous pemphigoid, and epidermolysis bullosa acquisita are autoimmune diseases of skin associated with considerable morbidity and sometimes mortality. There is no cure for these diseases.To summarize evidence-based treatments for these diseases by performing a systematic review.The research protocol included the following steps: identification of databases (...) be found. After the second-stage screening, 12 randomized controlled trials were analyzed, which included patients with pemphigus vulgaris or pemphigus vulgaris and pemphigus foliaceus, and 7 which included patients with bullous pemphigoid.Number of high-quality randomized controlled trials conducted on pemphigus and bullous pemphigoid is small. Oral corticosteroid along with a steroid-sparing agent appears to be the most effective treatment for pemphigus. Azathioprine may be most effective

2014 Indian journal of dermatology, venereology and leprology

50. British Association of Dermatologists guidelines for the management of pemphigus vulgaris

intraepithelial, mucocutaneous blistering. Desmoglein 3 is the major antigen, but 50–60% of patients have additional antibodies to desmoglein 1, the antigen targeted in pemphigus foliaceus (PF). 3–5 Although the pathogenesis of PV is complex, involving multiple pathways, 6 the underlying antibody pro?le is a major determinant of the clinical phenotype of PV. 5,7,8 The average mortality of PV was 75% before the introduc- tion of corticosteroids in the early 1950s. 9 This ?gure may be an underestimate due (...) British Association of Dermatologists guidelines for the management of pemphigus vulgaris GUIDELINES BJD British Journal of Dermatology British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017* K.E. Harman, 1 D. Brown, 2 L.S. Exton, 3 R.W. Groves, 4 P.J. Hampton, 5 M.F. Mohd Mustapa, 3 J.F. Setter?eld 4,6 and P.D. Yesudian 7 1 University Hospitals Leicester, Leicester Royal In?rmary, In?rmary Square, Leicester, LE1 5WW, U.K. 2 St John’s Institute

2017 British Association of Dermatologists

51. Increased risk of severe course of pemphigus in patients with pemphigus-associated alopecia: a prospective observational study. (PubMed)

pemphigus-associated alopecia. Alopecia was observed in 11/52 patients with pemphigus and scalp involvement: [0/28 (35.7%) with pemphigus vulgaris and 1/24 (4.2%) with pemphigus foliaceus. The clinical and immunological characteristics of these patients were analysed.Patients with pemphigus-associated alopecia had a significantly higher Pemphigus Disease Area Index total activity score compared with patients who had no pemphigus-associated alopecia (21.8 ± 18.6 and 11.0 ± 20.5, respectively; P = 0.02 (...) Increased risk of severe course of pemphigus in patients with pemphigus-associated alopecia: a prospective observational study. Pemphigus-associated alopecia is considered rare, and has not been studied in detail.To evaluate the clinical and immunological characteristics of patients with pemphigus-associated alopecia.This prospective observational study included 80 consecutive patients with histopathologically and immunopathologically confirmed pemphigus, of whom 11 (13.8%) were found to have

2018 Clinical & Experimental Dermatology

52. Epitope analysis of anti-desmoglein 1 autoantibodies from pemphigus foliaceus patients across different activity stages. (PubMed)

Epitope analysis of anti-desmoglein 1 autoantibodies from pemphigus foliaceus patients across different activity stages. Pemphigus foliaceus (PF) and pemphigus vulgaris (PV) are closely related, but clinically distinct, autoimmune blistering diseases caused by autoantibodies against desmoglein (Dsg)1 and Dsg3, respectively. Using ethylenediaminetetraacetic acid (EDTA)-treated Dsg3 enzyme-linked immunosorbent assay (ELISA) we have shown that the proportion of anti-Dsg3 antibodies against calcium

2015 British Journal of Dermatology

53. CTLA4 overexpressing adipose tissue-derived mesenchymal stem cell therapy in a dog with steroid-refractory pemphigus foliaceus (PubMed)

CTLA4 overexpressing adipose tissue-derived mesenchymal stem cell therapy in a dog with steroid-refractory pemphigus foliaceus Canine pemphigus foliaceus is an autoimmune antibody-mediated skin disease characterized by acantholysis. The objective of this case report is to present the successful management of steroid refractory pemphigus foliaceus with cytotoxic T-lymphocyte antigen 4 (CTLA4)-overexpressing adipose tissue mesenchymal stem cells (ATMSCs).A 10-year-old, 12.3-kg, castrated male (...) Shih Tzu presented with severe pruritus and anorexia. The diagnosis of pemphigus foliaceus was made based on its history, physical examination, and histopathology results of a skin biopsy. Treatment with prednisolone and combination therapy of other immunosuppressive drugs had failed; therefore, immunosuppressive gene, CTLA4 overexpressing ATMSCs (CTLA4-ATMSCs) and/or naive ATMSCs administration was performed with the consent of the owner. ATMSCs were administered 21 times over a period of 20

Full Text available with Trip Pro

2015 BMC veterinary research

54. Exacerbation of Pemphigus Foliaceus After Electron-beam Radiation. (PubMed)

Exacerbation of Pemphigus Foliaceus After Electron-beam Radiation. 24626406 2015 07 07 2014 10 23 1651-2057 94 6 2014 Nov Acta dermato-venereologica Acta Derm. Venereol. Exacerbation of pemphigus foliaceus after electron-beam radiation. 729-30 10.2340/00015555-1811 Kikuchi Kazuhiro K Department of Dermatology, Sapporo City General Hospital North 11, West 13, Chou-ku, Sapporo 060-8604, Japan. kikku@med.hokudai.ac.jp. Inokuma Daisuke D Moriuchi Reine R Koguchi-Yoshioka Hanako H Yasui Chikako C (...) Shimizu Satoko S eng Case Reports Journal Article Sweden Acta Derm Venereol 0370310 0001-5555 0 Adrenal Cortex Hormones 0 Ointments IM Administration, Cutaneous Adrenal Cortex Hormones administration & dosage Disease Progression Female Humans Middle Aged Ointments Paget Disease, Extramammary diagnosis radiotherapy Pemphigus diagnosis drug therapy etiology Radiation Injuries diagnosis drug therapy etiology Radiotherapy adverse effects Recurrence Remission Induction Skin Neoplasms diagnosis radiotherapy

Full Text available with Trip Pro

2014 Acta Dermato-Venereologica

55. Erythema annulare-like acantholytic dermatosis: A subset of pemphigus foliaceus. (PubMed)

Erythema annulare-like acantholytic dermatosis: A subset of pemphigus foliaceus. 24836841 2015 08 18 2014 12 19 1365-2133 171 6 2014 Dec The British journal of dermatology Br. J. Dermatol. Erythema annulare-like acantholytic dermatosis: a subset of pemphigus foliaceus. 1558-9 10.1111/bjd.13115 Holahan H M HM Rutgers New Jersey Medical School, Newark, NJ, U.S.A.; Department of Dermatology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, 52242, U.S.A. Farah R S RS (...) Selby J C JC Fairley J A JA eng Case Reports Letter Research Support, U.S. Gov't, Non-P.H.S. 2014 11 09 England Br J Dermatol 0004041 0007-0963 Annular Erythema IM Acantholysis pathology Biopsy, Needle Diagnosis, Differential Erythema pathology Female Humans Middle Aged Pemphigus pathology Skin Diseases, Genetic pathology 2014 5 20 6 0 2014 5 20 6 0 2015 8 19 6 0 ppublish 24836841 10.1111/bjd.13115

2014 British Journal of Dermatology

56. Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature. (PubMed)

Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature. 25496559 2016 02 01 2015 05 12 1365-2133 172 5 2015 The British journal of dermatology Br. J. Dermatol. Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature. 1420-3 10.1111/bjd.13586 de Sena Nogueira Maehara L L Centre for Blistering Diseases, Department of Dermatology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen (...) . eng Case Reports Letter Research Support, Non-U.S. Gov't Review 2015 03 31 England Br J Dermatol 0004041 0007-0963 0 Dermatologic Agents 4F4X42SYQ6 Rituximab IM Adult Aged Aged, 80 and over Chronic Disease Dermatologic Agents therapeutic use Epidemiologic Methods Female Humans Male Middle Aged Pemphigus drug therapy Rituximab therapeutic use Treatment Outcome 2014 12 16 6 0 2014 12 17 6 0 2016 2 2 6 0 ppublish 25496559 10.1111/bjd.13586

2014 British Journal of Dermatology

57. Presence of autoimmune regulator and absence of desmoglein 1 in thymoma associated with a pemphigus foliaceus patient. (PubMed)

Presence of autoimmune regulator and absence of desmoglein 1 in thymoma associated with a pemphigus foliaceus patient. 25523433 2016 04 12 2015 07 15 1365-2133 173 1 2015 Jul The British journal of dermatology Br. J. Dermatol. Presence of autoimmune regulator and absence of desmoglein 1 in a thymoma in a patient with pemphigus foliaceus. 268-71 10.1111/bjd.13617 Tsuchisaka A A Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell (...) Autoantigens 0 Desmoglein 1 0 Transcription Factors IM Aged, 80 and over Autoantigens metabolism Desmoglein 1 deficiency Female Humans Keratinocytes metabolism Pemphigus immunology Thymoma immunology Thymus Neoplasms immunology Transcription Factors metabolism 2014 12 20 6 0 2014 12 20 6 0 2016 4 14 6 0 ppublish 25523433 10.1111/bjd.13617

2014 British Journal of Dermatology

58. A patient with pemphigus foliaceus and myasthenia gravis treated by a cortisol secreting adrenal adenoma. (PubMed)

A patient with pemphigus foliaceus and myasthenia gravis treated by a cortisol secreting adrenal adenoma. 24931108 2015 09 21 2018 12 02 1365-2133 172 1 2015 Jan The British journal of dermatology Br. J. Dermatol. A patient with pemphigus foliaceus and myasthenia gravis treated by a cortisol-secreting adrenal adenoma. 280-2 10.1111/bjd.13185 Topham L L Department of Dermatology, Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, Stadium Road, London, SE18 4QH, U.K. Chapman A A Gibbs C (...) C Saha M M eng Case Reports Letter 2014 11 14 England Br J Dermatol 0004041 0007-0963 WI4X0X7BPJ Hydrocortisone IM Adenoma complications metabolism Adrenal Gland Neoplasms complications metabolism Adult Cushing Syndrome etiology Female Humans Hydrocortisone metabolism Myasthenia Gravis complications Pemphigus complications Remission, Spontaneous 2014 6 17 6 0 2014 6 17 6 0 2015 9 22 6 0 ppublish 24931108 10.1111/bjd.13185

2014 British Journal of Dermatology

59. Pemphigus. (PubMed)

often originates with painful oral erosions, and pemphigus foliaceus, which is characterised by exclusive skin lesions. Pemphigus is diagnosed on the basis of either IgG or complement component 3 deposits (or both) at the keratinocyte cell membrane, detected by direct immunofluorescence microscopy of a perilesional biopsy, with serum anti-Dsg1 or anti-Dsg3 antibodies (or both) detected by ELISA. Corticosteroids are the therapeutic mainstay, which have recently been complemented by the anti-CD20 (...) Pemphigus. Pemphigus consists of a group of rare and severe autoimmune blistering diseases mediated by pathogenic autoantibodies mainly directed against two desmosomal adhesion proteins, desmoglein (Dsg)1 and Dsg3 (also known as DG1 and DG3), which are present in the skin and surface-close mucosae. The binding of autoantibodies to Dsg proteins induces a separation of neighbouring keratinocytes, in a process known as acantholysis. The two main pemphigus variants are pemphigus vulgaris, which

2019 Lancet

60. Reviewing putative industrial triggering in pemphigus: cluster of pemphigus in the area near the wastewater treatment plant (PubMed)

Reviewing putative industrial triggering in pemphigus: cluster of pemphigus in the area near the wastewater treatment plant A range of pemphigus is relatively rare potentially fatal group of autoimmune blistering dermatoses. Usually, there is no apparent triggering, while in some predisposed patients there are alleged environmental/industrial inducing factors. In a short time period (4 years), we diagnosed 3 novel cases of pemphigus (1 pemphigus vulgaris, 1 pemphigus foliaceus and 1 shift from (...) pemphigus foliaceus into pemphigus vulgaris) at a clinical and laboratory level (ELISA, immunofluorescence studies). We discuss a possible common inducing mechanism as these patients inhabit one estate of the Poznan suburbia (Kozieglowy, population < 12,000), Greater Poland district, Poland, and review literature data on alleged pemphigus triggers. To the best of our knowledge, this is the first report exploring the putative association between pemphigus diseases and wastewater treatment plant

Full Text available with Trip Pro

2017 Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>